USFDA Guidance: Establishing Impurity Specifications for Antibiotics and NIOSH-Approved Air-Purifying Respirators Compliance Policy
- Sharan Murugan
- Apr 20
- 3 min read
The FDA continues to strengthen regulatory expectations across both pharmaceutical quality and medical device oversight, with two important draft guidances issued in April 2026. The guidance Establishing Impurity Specifications for Antibiotics (April 2026, Draft) and Compliance Policy Regarding Premarket and Other Requirements for Certain NIOSH Approved Air-Purifying Respirators (April 20, 2026, Draft) provide structured recommendations for industry and regulators.
Introduction
This draft guidance provides recommendations for establishing impurity specifications in antibiotics, particularly those produced by fermentation and semi-synthetic processes. It aims to ensure that antibiotic drug substances and products meet appropriate standards of quality, safety, and purity.
Background
Antibiotics manufactured through fermentation or semi-synthesis are inherently more complex than chemically synthesized drugs. These processes generate mixtures of compounds, including active components and impurities, requiring more detailed control strategies. Existing ICH guidelines address impurities in chemically synthesized drugs, but they do not fully cover fermentation-based antibiotics. This guidance fills that gap by outlining approaches for identifying and controlling impurities in such products.
Scope
The guidance applies to antibiotic drugs submitted under:
New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs)
Over-the-counter monograph drugs
Investigational new drug applications (INDs), based on general principles
It focuses on impurities and degradation products, excluding other elements such as residual solvents, microbiological controls, and leachables.
Listing of Impurities and Degradation Products
Specifications for antibiotics should include a structured listing of impurities and degradation products. For drug products, this includes identified and unidentified degradation products, unspecified degradation products within thresholds, and total degradation products.
For drug substances, specifications should include identified and unidentified impurities, unspecified impurities within thresholds, and total impurities.
Analytical Procedures
Analytical procedures used to detect impurities must be scientifically sound, validated, and suitable for their intended use. Validation should demonstrate parameters such as specificity, accuracy, precision, and robustness, ensuring that impurity levels can be reliably measured under actual conditions.
Establishing Acceptance Criteria
Acceptance criteria for impurities and degradation products should be based on scientific evidence, including clinical data, nonclinical studies, prior knowledge, and comparative analysis with reference products.
If impurity levels exceed ICH qualification thresholds, justification must be provided, including toxicological evaluation. Special consideration is required for mutagenic impurities, following ICH M7 principles.
Application-Specific Considerations
For NDAs, impurity limits should align with ICH thresholds unless justified otherwise through safety data.
For ANDAs, applicants may use compendial standards, comparative analysis with reference listed drugs, or threshold-based approaches. For OTC monograph drugs, impurity specifications should follow USP or alternative compendial standards, ensuring safety and compliance.
This draft guidance outlines a proposed compliance policy for certain NIOSH-approved air-purifying respirators, including N95 respirators and other filtering facepiece respirators used for medical purposes.
Respirators used for medical purposes are regulated as medical devices under the FD&C Act. Their classification depends on intended use, including protection against disease transmission.
Certain respirators are classified as Class II devices, while others may be “not classified” and subject to different regulatory pathways.
Compliance Policy
The FDA proposes not to prioritize enforcement of certain regulatory requirements for these devices, including:
Premarket notification (510(k))
Registration and listing
Labeling requirements
Quality system requirements (with some exceptions)
Unique device identification requirements
However, manufacturers must still comply with recordkeeping and complaint handling requirements to support postmarket oversight.
Rationale for the Policy
The policy is based on:
NIOSH’s rigorous approval and oversight processes, including testing, audits, and conformity assessments
FDA’s review of postmarket data, which did not identify significant safety concerns
This allows the FDA to adopt a least burdensome approach while maintaining safety.
Devices Outside Scope
The guidance does not apply to respirators with additional features such as antimicrobial coatings, drug delivery systems, or novel technologies. These products may require full regulatory review and approval.
For complete official guidance, refer to:
Comments